LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Blood Test Could Confirm COVID-19 Vaccination in Minutes

By LabMedica International staff writers
Posted on 07 Jun 2021
Print article
Image: An image taken from a YouTube video shows results of a rapid blood test developed by Johns Hopkins researchers that can confirm in minutes if a person has been vaccinated for SARS-CoV-2, the virus that causes COVID-19 (Photo courtesy of Robert Kruse)
Image: An image taken from a YouTube video shows results of a rapid blood test developed by Johns Hopkins researchers that can confirm in minutes if a person has been vaccinated for SARS-CoV-2, the virus that causes COVID-19 (Photo courtesy of Robert Kruse)
Researchers have developed a rapid blood test that can confirm in minutes if a person has been vaccinated for SARS-CoV-2, the virus that causes COVID-19.

The rapid blood test developed by scientists at the Johns Hopkins University (JHU; Baltimore, MD, USA) could confirm a person has been vaccinated while they wait to board a plane or enter a sporting event. Their COVID-19 antibody test is similar to one used at home to determine blood type, where the user pricks a finger and places a drop of blood on a card. A fusion protein developed by the research team is housed on the card and detects COVID-19 antibodies, tiny proteins in the blood the immune system produces to “remember” viral encounters and provide immunity to future infections. Results come back in less than five minutes, faster than current lateral flow tests to detect antibodies at point of care, while also potentially providing a clearer result. Immunocompromised patients, who studies have shown don’t always respond to the COVID-19 vaccine, could test their antibody level and see if the vaccine is working for them, according to the researchers.

The test uses hemagglutination, in which the degree of clumping together of red blood cells reveals the concentration of antibodies. The hemagglutination results could let people know if they still have protection months after they received the vaccine or if they need a booster shot. The degree of hemagglutination also correlated with levels of neutralizing antibodies in patients, which protect against viral infection. In a study on 400 blood samples, half of which were from prior COVID-19 patients, the test correctly identified antibodies in previously infected patients 87.5% of the time, a slightly higher rate than ELISA tests performed in hospitals that require hours to perform. The test could be used to confirm a person’s vaccination instead of having to show a vaccine card, according to Robert Kruse, M.D., Ph.D., who created the blood test.

“If a business is using the honor system for vaccinations, now they could test people on-site,” said Kruse.

Related Links:
Johns Hopkins University

Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.